Caris Life Sciences Luxembourg Holdings, S.a.r.l.

Caris Life Sciences Switzerland Holdings Gmbh

Caris Mpi, Inc.

Caris Life Sciences

Christine Kuslich

Michael Klass

George Poste

David Spetzler

Daniel D Von Hoff

Alan Wright

Traci Pawlowski

Robert J Penny

Arlet Alarcon

Ryan P Bender

David M Loesch

David D Halbert

Andrea Tasinato

Daniel Holterman

Matthew J Mcginnis

Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.

Circulating biomarkers for metastatic prostate cancer

Biomarkers for theranostics

Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

Methods and systems of using exosomes for determining phenotypes

Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.

Methods for assessing RNA patterns

Growing community of inventors

Gilbert, AZ, United States of America

Christine Kuslich